spectrin repeat containing nuclear envelope protein 2Genealiases: EDMD5 · KASH2 · NUA · NUANCE · Nesp2 · Nesprin-2
Q-omics provides the consensus-scored SYNE2 profile across patient tissues and cancer cell-line models. SYNE2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SYNE2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SYNE2 RNA expression shows 20,844 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where SYNE2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYNE2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYNE2 survival associations across molecular data types. SYNE2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (11) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYNE2 RNA expression–survival associations across cancer types. High SYNE2 expression shows unfavorable associations in UVM and THCA, but favorable associations in KIRC, HNSC, UCS and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SYNE2 RNA expression.
This table summarizes SYNE2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SYNE2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYNE2 shows lower tumor expression in KIRC, THCA, KICH, BRCA and COAD and higher tumor expression in STAD. The KIRC box plot shows higher SYNE2 RNA expression in normal versus tumor tissue (log2 FC = −1.041, t-test p < 0.001).
This table shows molecular features associated with SYNE2 in patient tissues and cancer cell lines. In patient samples, SYNE2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SYNE2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
